Kensey Nash lowers guidance till year end
This article was originally published in Clinica
Kensey Nash has warned that its revenues and earnings for the quarter and the rest of the year will be lower than expected, due to a shortfall in the orthopaedics sector segment of the biomaterials business. Shares in the biomaterials company dropped 27% to just over $16 on the news.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.